Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 3/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22312249 | 0.85 | KMT2A (0.52) | ALDH1A1SMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL1016036 | 0.82 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL1019064 | 0.81 | PPIB (0.52) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL6577164 | 0.81 | MAPT (0.47) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6577161 | 0.81 | MAPT (0.47) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL7422040 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL3936872 | 0.79 | MAPT (0.60) | ALDH1A1SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL3154611 | 0.78 | TMEM97 (0.55) | ALDH1A1SMN1; SMN2LMNACRHBPCRHR2 | |
| SCHEMBL6578789 | 0.78 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL6780965 | 0.77 | CNR2 (0.45) | ALDH1A1NPC1RAB9ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| CN-103224497-A | Inhibitors of protein kinases | PORTOLA PHARM INC | 2013-07-31 | — | — | CN | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | ALDH1A1 3049/4885SMN1; SMN2 4561/4885NPC1 2993/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | ALDH1A1 3049/4885SMN1; SMN2 4561/4885NPC1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.